Biocon will be watched. Ogivri, a biosimilar Trastuzumab jointly developed by Biocon and Mylan, has been approved in the European Union (EU). The announcement was made before market hours today, 19 December 2018.
The European Commission has granted Marketing Authorization for Ogivri to ...read more